Last reviewed · How we verify

NCT05614206

Biomarkers Trajectories of Early Intervention in Siblings of Children with Autism Spectrum Disorder

Completed NA Last updated 14 March 2025
What this trial tests

NA trial testing Behavioral intervention based on Applied Behavior Analysis principles in Autism Spectrum Disorder in 80 participants. Completed in 26 September 2024.

Timeline
26 September 2022
Primary endpoint
26 September 2023
26 September 2024

Quick facts

Lead sponsorIRCCS Eugenio Medea
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment80
Start date26 September 2022
Primary completion26 September 2023
Estimated completion26 September 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Eugenio Medea — full company profile →

Who can join

Adults 18 Months to 24 Months, any sex, with Autism Spectrum Disorder or Early Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project deals with essential challenges in the context of Autism Spectrum Disorder benefiting from a prospective design in childhood, early intervention and a cutting-edge experimental techniques. The present study tests the potential effect of early intervention on neural and behavioral responses in toddlers at elevated likelihood of developing autism (siblings of children with autism) who show clinical autistic signs. Four comparison groups were included in the study: (1) toddlers at elevated likelihood of developing autism with clinical autistic signs who receive early intervention from 18 to 24 months (2) toddlers at elevated likelihood of developing autism with clinical autistic signs who do not receive early intervention (3) toddlers at elevated likelihood of developing autism without clinical autistic signs who only received assessment and monitoring, and (4) typically developing toddlers who only received assessment and monitoring. This study focuses on social and nonsocial sensory integration skills (measured by electroencephalographic and eyetracking recordings) to identify reliable biomarkers for early detection and intervention of autism during a critical period of development. The characterization of biomarkers will guide the detection of the most vulnerable children that will benefit from early intervention, with the long-term aim of reducing the impact of autism on the National Health System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other IRCCS Eugenio Medea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05614206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing